SEC Form 4 · accession 0000880771-16-000212
SCICLONE PHARMACEUTICALS INC · SCLN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Carey Chern
Officer — General Counsel
Period of report
Nov 14, 2016
Accepted (ET)
Nov 15, 2016 · 4:25 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000880771
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Incentive Stock Option (right to buy)F1,F2 | $10.35 | Nov 14, 2016 | A | 38,644 | A | — | Nov 14, 2026 | Common Stock | 38,644 | 38,644 | D |
| Non-Qualified Stock Option (right to buy)F1,F2 | $10.35 | Nov 14, 2016 | A | 41,356 | A | — | Nov 14, 2026 | Common Stock | 41,356 | 41,356 | D |
| Restricted Stock UnitF1,F3 | $0.00 | Nov 14, 2016 | A | 30,000 | A | — | — | Common Stock | 30,000 | 30,000 | D |
Explanation of responses
- F1Granted under the Issuer's 2015 Equity Incentive Plan.
- F225% of such shares vest on October 24, 2017 and 2.0833% vests each month thereafter provided that the Reporting Person continues to be employed by the Issuer.
- F3Vesting for such RSUs will occur 25% on October 24, 2017, 25% on October 24, 2018, 25% on October 24, 2019, and 25% on October 24, 2020, or, in the discretion of the Company, such later date on which the sale of the Stock to be issued in settlement of such Unit would not violate the Trading Compliance Policy.